Increased dose at parametrium using intensity modulated radiotherapy in locally advanced cervical cancer treated with 2D brachytherapy

Not Applicable

Recruiting

• Conditions: Cervical cancer; Cancer - Cervical (cervix)

• Registration Number: ACTRN12624000211561
• Lead Sponsor: Vajira hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-01
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 39

Inclusion Criteria

squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of uterine cervix FIGO stage IB3-IVa with/without inguinal node metastases aged at least 18 years ECOG 0-2

Exclusion Criteria

-other primary malignancies except carcinoma in situ of cervix and basal cell carcinoma of skin -previous hysterectomy -previous pelvic or abdominal radiotherapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ocal control defined as no recurrence in vagina, cervix, uterus and parametrium[Physical examination and radiographic studies including MRI or CT scan of pelvis baseline, 3 years following end of treatment]

Secondary Outcome Measures

Name	Time	Method
Regional control defined as no recurrence of pelvic and paraaortic lymph node[Radiographic studies including MRI or CT scan of pelvis with/without upper abdomen baseline, 3 years following end of treatment];toxicity[History, physical examination, radiographic studies including MRI or CT scan of pelvis, scope baseline, 3 years following end of treatment];Distant control defined as no recurrence in any organs excluding local and regional recurrences[Physical examination, CT of chest and whole abdomen baseline, 3 years following end of treatment];overall survival[death certificates baseline, 3 years following end of treatment];cancer specific survival[Physical examination, radiographic studies including MRI or CT scan of pelvis and upper abdomen, CT of chest and death certificates baseline, 3 years following end of treatment];quality of life[EORTC QLQ-C30 questionnaires baseline, 3 years following end of treatment];quality of life[EORTC QLQ-CX24 questionnaires baseline, 3 years following end of treatment]